Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Large-Cell, Anaplastic 3Immunoblastic Lymphadenopathy 3Esophageal Neoplasms 3Burkitt Lymphoma 3Adenocarcinoma Of Esophagus 3Sarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Sezary Syndrome 1Rhabdoid Tumor 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1

Interventions

Dexamethasone 17Melphalan 14Bortezomib 10Calcium Dobesilate 8Filgrastim 6Granulocyte Colony-Stimulating Factor 5Cyclophosphamide 5birtamimab 4dexamethasone acetate 3Whole-Body Irradiation 3Thalidomide 3Peripheral Blood Stem Cell Transplantation 3Lenalidomide 3fludarabine phosphate 2daratumumab 2Mycophenolic Acid 2Etoposide 2Doxycycline 2Darbepoetin alfa 2Cyclosporine 2Busulfan 2Blood Component Removal 2pomalidomide 1pegfilgrastim 1ixazomib 1isatuximab 1ferrous sulfate 1ferric gluconate 1dexamethasone 21-phosphate 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Immunoglobulin Light-chain Amyloidosis × Microarray Analysis × Clear all
NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
35 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡